Louis C. Drapeau

AmpliPhi Biosciences Corp.

Louis C. Drapeau

Louis C. Drapeau

AmpliPhi Biosciences Corp.

Overview
Career Highlights

Nektar Therapeutics
Arthur Andersen LLP
BioMarin Pharmaceutical, Inc.

RelSci Relationships

2350

Number of Boards

7

Birthday

1944

Age

75

Relationships
RelSci Relationships are individuals Louis C. Drapeau likely has professional access to. A relationship does not necessarily indicate a personal connection.

Managing Director at BioScience Managers Pty Ltd

Relationship likelihood: Strong

Former Chief Executive Officer & Non-Executive Director at Avita Medical Ltd.

Relationship likelihood: Strong

President & Chief Executive Officer at Vical, Inc.

Relationship likelihood: Strong

Professional at Theragence, Inc.

Relationship likelihood: Strong

Former Chairman of the Board, President & Chief Executive Officer at Bio-Rad Laboratories Inc.

Relationship likelihood: Strong

Co-Founder at Bio-Rad Laboratories Inc.

Relationship likelihood: Strong

Managing Director at Gemini Advisors LLC

Relationship likelihood: Strong

Vice President & Treasurer at Bio-Rad Laboratories Inc.

Relationship likelihood: Strong

Former Professor at University of Washington

Relationship likelihood: Strong

Chief Executive Officer & Director at Arog Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Louis C. Drapeau
Potential Connections via
Relationship Science
You
Louis C. Drapeau
AmpliPhi Biosciences Corp.
Education
BS in Mechanical Engineering

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Masters in Business Administration

The Stanford Graduate School of Business has built an international reputation based on its innovative programs, which include: Two-year MBA Program, designed to educate business leaders One-year Stanford Sloan Master’s Program for mid-career executives PhD Program for future academics Executive Education programs for experienced managers Faculty research program Academic programs, including the two-year MBA, the 12-month Sloan Master's Program, and the PhD program, create a transformational student experience that reflects the tagline: Change lives. Change organizations. Change the world. Today the state-of-the-art Knight Management Center complex enables Stanford's innovative, globalized MBA curriculum, offering flexible classroom spaces for hands-on experiential learning small-group leadership labs, and team-based learning. It engages faculty and students across Stanford University, as well as alumni, global executives, and the broader world community.

Career History
Chief Financial Officer, Principal Accounting Officer & Vice President
2007 - 2016

InSite Vision Inc. develops and markets ophthalmic pharmaceutical products that designs to treat a range of common eye problems, including ocular infection, pain and inflammation in ocular surgery, and glaucoma. Its products include AzaSite, Besivance, AzaSite Plus, DexaSite, AzaSite Xtra, and ISV-10 and 303. The company was founded by Merwin Jerry Hansen in 1986 and is headquartered in Alameda, CA.

Managing Partner
1971 - 2002

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Acting Chief Executive Officer
2002 - 2005

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Boards & Committees
Independent Non-Executive Director
2016 - Current

Avita Medical Ltd. engages in the development and distribution of regenerative and respiratory medicine and treatments. It operates through the following segments: Asia Pacific, Europe, and Americas. The Asia Pacific, Europe, and Americas segments involve in the sale of RECELL Devices. The company was founded on December 21, 1992 and is headquartered in Royston, the United Kingdom.

Lead Director, Board of Directors
2008 - 2012

Bionovo, Inc. is a clinical drug discovery and development company, which is focused on developing drugs for the treatment of unmet medical needs in women's health and cancer. The company was founded by Isaac Cohen and Mary Tagliaferri in February 2002 and is headquartered in Emeryville, CA.

Director
Current

Surface Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm's current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is headquartered in San Diego, CA.

Political Donations
$500
1999

Former President of United States

Transactions
Details Hidden

InSite Vision, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Louis C. Drapeau. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Louis C. Drapeau's profile does not indicate a business or promotional relationship of any kind between RelSci and Louis C. Drapeau.